Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

After A Big Rally, What Propels Lonza Now?

I've always been a little surprised at how willing investors can be to bid up the manufacturers of pharmaceutical components. While these are fine specialty chemical businesses, nothing about the revenue or margins (or the persistence of either) is particularly outstanding. Be that as it may, investors have certainly taken a more positive view on Switzerland's Lonza (OTCPK:LZAGY) over the past 18 months as the company has digested its Arch Chemicals acquisition and a new CEO who appears more focused on margins and returns than growth for the sake of growth.

On one hand, I do like Lonza's capabilities in small molecules, peptides, and monoclonal antibodies. On the other hand, recent contract wins by Samsung Biologics highlight that...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details